Joel Rurik: CAR-T Therapies to Reverse Cardiac Fibrosis
Injury to heart tissue results in non-functional scar tissue that compromises cardiac function. A new approach combines targeted lipid nanoparicles and mRNAs to reprogram immune cells to seek and destroy the pathogenic fibroblasts that limit heart functio
Talking Biotech with Dr. Kevin Folta · Colabra
Audio is streamed directly from the publisher (media.transistor.fm) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Injury to organs frequently results in impaired function due to the formation of scar tissue. Heart attacks and chronic high blood pressure can induce the formation of pathogenic fibroblasts, cells that lose their original function, yet maintain some structural element of the injured tissue. The formation of fibrogenic tissue affects a significant portion of the population, and contributes to decline associated with many diseases, such as congestive heart failure or liver cirrhosis. A new technology uses targeted lipid nanoparticles to reprogram T-cells to attack pathogenic fibroblasts.